SOPHIRIS BIO INC. 8-K SEC Filings

If this box is checked, additional Borrowers ("Additional Borrowers") are listed in the Annex attached hereto (Borrower and such Additional Borrowers, collectively, "Borrower").

Sophiris Bio Inc. will not complete its financial audit for the year-ended December 31, 2019 in an effort to conserve its cash resources. The Company has not filed, nor is it planning to file its Annual Report on Form 10-K for the year-e...

We have read the statements made by Sophiris Bio Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Sophiris Bio Inc. dated March 31, 2020. We agree w...

SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 – Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage c...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

SAN DIEGO and VANCOUVER, British Columbia, November 7, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treat...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on August 26, 2019, Sophiris Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed...

This Securities Purchase Agreement (this “Agreement”) is dated as of August 26, 2019, between Sophiris Bio Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including...

SAN DIEGO and VANCOUVER, British Columbia, August 9, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage c...

The 2019 Annual General Meeting of Shareholders (the “Annual Meeting”) of Sophiris Bio Inc. (the “Company”) was held on June 27, 2019. As of April 30, 2019, the record date for the Annual Meeting, 30,217,140 common shares were outstandin...

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-st...

SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late...

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.